HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US COVID-19 Fraud: After Facebook Posts, Regulators Don’t ‘Friend’ ChromaDex

Executive Summary

ChromaDex is among latest targets of FDA/FTC joint warnings identifying claims on websites as well as in social media posts that render products unapproved and misbranded drugs indicated to prevent or treat COVID-19.

You may also be interested in...



Separation Key To Posting Studies Linking Dietary Ingredients To Preventing Or Treating Disease

DSHEA’s Scientific Literature Exemption is attracting attention for offering online studies showing nutrients’ benefits on diseases including COVID-19, though the method isn’t free of risks, suggests CRN executive Megan Olsen.

ChromaDex Loss Down, Tru Niagen Sales Up 22%

Q3 net sales were up 18% and its net loss dropped $3m, the provider of Tru Niagen products containing Niagen, its proprietary form of nicotinamide riboside, reported five days before announcing Tru Niagen stick packs are available under the EX brand in Hong Kong exclusively at A.S. Watson Group’s stores and website.

Fewer Warnings But Recalls Rising As US FDA Stems Pandemic Fraud Tide

Warning letters noting the coronavirus have slowed to a drip in the US while recalls continue climbing for products already identified in warnings.

Related Content

Topics

UsernamePublicRestriction

Register

RS150756

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel